Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Anxiety, Depression, Mood Disorders, Bipolar Disorders, Eating Disorders, and Psychotic Disorders), Product (Consumables, Instruments, and Software and Services), Test Type (Whole Genome Sequencing and Chromosomal Array Based Tests), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Patient Type (Adult, Geriatric, and Child), End User (Hospital and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others)- Industry Trends and Forecast to 2032
.
The Global Pharmacogenetic Testing Market size was valued at USD 610.34 USD Million in 2024.
The Global Pharmacogenetic Testing Market is projected to grow at a CAGR of 10.4% during the forecast period of 2025 to 2032.
The major players operating in the market include PerkinElmer Inc., IlluminaInc., Thermo Fisher Scientific Inc., Dynamic DNA Laboratories, Sonic Healthcare, QIAGEN, Eurofins Scientific, 23andMeInc, OneOme, BGI, PacBio, MD Labs, GENEWIZ, PGXT, Luminex Corporation, and Myriad GeneticsInc., .
The market report covers data from the North America.
